[Infliximab therapy for inflammatory bowel disease: seven years on]
O Segarra Cantón1, D Infante Pina, R Tormo Carnicé
1Unidad de Gastroenterología, Hepatología y Nutrición Pediátrica, Hospital Materno-Infantil Vall d'Hebron, Barcelona, España. oscarsegarra@hotmail.com
Anales De Pediatria (Barcelona, Spain : 2003)
|October 24, 2007
Summary
Infliximab showed varying efficacy in pediatric inflammatory bowel disease, with good results in Crohn's disease but limited effectiveness in indeterminate colitis. Further pediatric studies are needed to confirm these findings.
Area of Science:
- Pediatric Gastroenterology
- Immunology
- Pharmacology
Context:
- Inflammatory bowel disease (IBD) presents significant challenges in pediatric populations.
- Infliximab, a biologic agent, has emerged as a treatment option for IBD.
- Understanding its efficacy and safety in children is crucial for clinical practice.
Purpose:
- To evaluate the clinical experience and efficacy of infliximab in pediatric patients with IBD at a single center.
- To analyze treatment outcomes based on specific IBD diagnoses (Crohn's disease, ulcerative colitis, indeterminate colitis).
Summary:
- Retrospective review of 14 pediatric IBD patients (9 Crohn's, 3 ulcerative colitis, 2 indeterminate colitis) treated with infliximab.
- Significant clinical remission achieved in Crohn's disease (80% at week 10) and ulcerative colitis (initially 100%, 33% long-term).
- Limited efficacy in indeterminate colitis; adverse events included infusion reactions and infections.
Impact:
- Infliximab demonstrates differential efficacy across pediatric IBD subtypes, being most effective in Crohn's disease.
- Findings highlight the need for further randomized controlled trials in pediatric IBD to establish optimal treatment strategies.
- The study contributes to the understanding of infliximab's role in managing pediatric IBD.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...